Ministry of Food et al., 2017-12-14: Korean MFDS product record for ProvayBlue 0.5% (methylene blue) injection, licensed 2017-12-14 to Samoh Pharm with Cenexi as contract manufacturer; the approved indication is drug-induced methemoglobinemia and the approved dose is 1-2 mg/kg intravenously.
메틸렌블루로서 체중 kg당 1~2mg(0.2~0.4mL)을 5분 이상에 걸쳐 매우 천천히 정맥주사하여야 한다.
Ministry of Food et al., 2017-12-14: Korean MFDS product record for ProvayBlue 0.5% (methylene blue) injection, licensed 2017-12-14 to Samoh Pharm with Cenexi as contract manufacturer; the approved indication is drug-induced methemoglobinemia and the approved dose is 1-2 mg/kg intravenously. C4 Korea – approval record. Product: 프로베블루주0.5%(메틸렌블루), 5 mg methylene blue per mL (EP grade, trihydrate), item code 201708376, approval date 2017-12-14, professional prescription medicine. Indication field (효능효과): '약물에 의한 메트헤모글로빈혈증' (drug-induced methemoglobinemia). Dosage field as quoted: 1-2 mg/kg (0.2-0.4 mL) IV over at least 5 minutes, repeatable after 1 hour, total cumulative dose not to exceed 7 mg/kg; diluted in 5% dextrose, never with 0.9% saline. Label warns against subcutaneous, subdural or intrathecal injection and against use in G6PD deficiency. Korean-language quote; non-Latin quote, hand-check. Record field (label table text), hence the quote is a record field rather than article prose. Study type: regulatory record.
